Practical Approach to Managing PNH: Q&A.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 14
- By:
- Publication type:
- Article
Works matching IS 15430790 AND DT 2025 AND VI 23
Results: 69
1
2
Dual Therapy: Danicopan as Add-on Therapy to C5 Inhibitors.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 12
- By:
- Publication type:
- Article
3
Monotherapy With Upstream or Alternative Pathway Inhibitors.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 10
- By:
- Publication type:
- Article
4
Monotherapy With Terminal Pathway C5 Inhibitors.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 7
- By:
- Publication type:
- Article
5
Complement Inhibitors: A Significant Advance in the Treatment of PNH.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 5
- By:
- Publication type:
- Article
6
About PNH: Brief Overview.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 3
- By:
- Publication type:
- Article
7
Navigating the Paroxysmal Nocturnal Hemoglobinuria (PNH) Landscape.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 1
- By:
- Publication type:
- Article
8
Current Utilization of Molecular Residual Disease (MRD) Testing in Colorectal Cancer: Q&A.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 10
- By:
- Publication type:
- Article
9
Identification of Colorectal Cancer Recurrence Risk Using Circulating Tumor DNA.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 6
- By:
- Publication type:
- Article
10
The Transformative Potential of Circulating Tumor DNA as a Biomarker for Detecting Molecular Residual Disease in Colorectal Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 2
- By:
- Publication type:
- Article
11
The Promise of Molecular Residual Disease (MRD) Testing for Patients With Colorectal Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 1
- By:
- Publication type:
- Article
12
Modern Approaches in Neuroendocrine Tumors (NETs).
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 1
- By:
- Publication type:
- Article
13
KEYMAKER-U03 Substudy 03B: Pembrolizumab and Targeted Therapy Combinations for Advanced Clear Cell Renal Cell Carcinoma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 13
- By:
- Publication type:
- Article
14
Current Utilization of Molecular Residual Disease (MRD) Testing in Colorectal Cancer: Q&A.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 10
- By:
- Publication type:
- Article
15
Identification of Colorectal Cancer Recurrence Risk Using Circulating Tumor DNA.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 6
- By:
- Publication type:
- Article
16
The Transformative Potential of Circulating Tumor DNA as a Biomarker for Detecting Molecular Residual Disease in Colorectal Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 2
- By:
- Publication type:
- Article
17
The Promise of Molecular Residual Disease (MRD) Testing for Patients With Colorectal Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 1
- By:
- Publication type:
- Article
18
The Development of ATR Inhibitors.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 185
- By:
- Publication type:
- Article
19
Treatment Deintensification in Locally Advanced Rectal Cancer: When Less Is More.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 182
- By:
- Publication type:
- Article
20
Radiation Therapy and MRI-Based Treatments in Non-Small Cell Lung Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 179
- By:
- Publication type:
- Article
21
Development of Chimeric Antigen Receptor Natural Killer-Cell Therapy.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 176
- By:
- Publication type:
- Article
22
Advances in Uterine Serous Carcinoma and Uterine Carcinosarcoma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 173
- By:
- Publication type:
- Article
23
Genetics of Prostate Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 144
- By:
- Publication type:
- Article
24
Cabozantinib in Patients With Non-Locally Pretreated Brain Metastases From Renal Cell Carcinoma: Results of the Multicenter CABRAMET Phase II Trial (NCT03967522).
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 19
- By:
- Publication type:
- Article
25
Casdatifan Monotherapy in Patients With Previously Treated Clear Cell Renal Cell Carcinoma: Safety, Efficacy and Subgroup Analysis Across Multiple Doses from ARC-20, a Phase 1 Open-Label Study.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 18
- By:
- Publication type:
- Article
26
Racial Disparities in Renal Cell Carcinoma Histology and Outcomes: Insights From the French Kidney Cancer Research Network (UroCCR-191).
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 16
- By:
- Publication type:
- Article
27
Lenvatinib Plus Tislelizumab as First-Line Therapy for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Single-Center, Single-Arm, Phase II Study.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 15
- By:
- Publication type:
- Article
28
Nivolumab Plus Cabozantinib vs Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma: Final Follow-Up Results From the CheckMate 9ER Trial.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 11
- By:
- Publication type:
- Article
29
Cabozantinib in Combination With Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma: Final Results of COSMIC-313.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 2
- By:
- Publication type:
- Article
30
Modern Approaches in Neuroendocrine Tumors (NETs).
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 2
- By:
- Publication type:
- Article
31
Achieving Durable Response With the TRK Inhibitor Larotrectinib, and Possible Discontinuation of Therapy in Pediatric NTRK Gene Fusion–Positive Solid Tumors.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 2
- By:
- Publication type:
- Article
32
PARP Inhibition in HRR Gene--Mutated Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 2, p. 90
- By:
- Publication type:
- Article
33
Is There a New Standard-of-Care Therapy for Advanced Hodgkin Lymphoma?
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 2, p. 76
- By:
- Publication type:
- Article
34
Update on PARP Inhibitors for the Treatment of Ovarian Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 2, p. 100
- By:
- Publication type:
- Article
35
A Common Cause.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 2, p. 66
- By:
- Publication type:
- Article
36
Thrombosis in Immune Thrombocytopenia.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 2, p. 87
- By:
- Publication type:
- Article
37
Ethics in Medicine: Avoiding Conflicts of Interest in Prescribing.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 2, p. 93
- By:
- Publication type:
- Article
38
The Use of Fixed-Dose Regimens in Chronic Lymphocytic Leukemia.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 2, p. 84
- By:
- Publication type:
- Article
39
Management of Toxicities From Antibody-Drug Conjugates.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 2, p. 96
- By:
- Publication type:
- Article
40
Targeting RAS in Gastrointestinal Malignancies.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, n. 2, p. 111
- By:
- Publication type:
- Article
41
Golcadomide ± Rituximab Demonstrates Durable Efcacy and Is Well Tolerated in Patients With R/R FL: Updated Results From the Phase 1/2 CC-99282-NHL-001 Study.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 13
- Publication type:
- Article
42
Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients With R/R FL: 2-Year Follow-up From Arm 2 of the EPCORE NHL-2 Trial.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 12
- Publication type:
- Article
43
Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 10
- Publication type:
- Article
44
Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients With Previously Untreated DLBCL With High-Risk Features: Long-Term Results From the EPCORE NHL-2 Trial.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 8
- Publication type:
- Article
45
Three-Year Update From the EPCORE NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in R/R LBCL.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 7
- Publication type:
- Article
46
Longer Follow-up of Golcadomide, a Cereblon E3 Ligase Modulator (CELMoD™) Agent, ± Rituximab in Patients With R/R DLBCL.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 5
- Publication type:
- Article
47
Tafasitamab + Lenalidomide and Rituximab for R/R FL: Results From a Phase 3 Study (inMIND).
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 3
- Publication type:
- Article
48
Golcadomide + R-CHOP Has High MRD Negativity Across High-Risk, Untreated a-BCL.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 2
- Publication type:
- Article
49
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2- Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 13
- Publication type:
- Article
50
AFT-38 PATINA: A Randomized, Open-Label, Phase 3 Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for HR+/HER2+ Metastatic Breast Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2025, v. 23, p. 12
- Publication type:
- Article